Ruxolitinib, a JAK1/2 inhibitor that is already approved for use in hematologic malignancies, is a therapy of interest in ENKTL, given pre-clinical work that JAK1/2 inhibition can disrupt JAK/STAT signaling in STAT3-mutated or overexpressed ENKTL [46]. Here, JAK1 is linked to hematologic disorder.